These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 27683183)
1. Kato S; Subbiah V; Marchlik E; Elkin SK; Carter JL; Kurzrock R Clin Cancer Res; 2017 Apr; 23(8):1988-1997. PubMed ID: 27683183 [No Abstract] [Full Text] [Related]
2. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450 [TBL] [Abstract][Full Text] [Related]
3. An integrative pan cancer analysis of RET aberrations and their potential clinical implications. Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072 [TBL] [Abstract][Full Text] [Related]
4. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Helsten T; Kato S; Schwaederle M; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R Mol Cancer Ther; 2016 Jul; 15(7):1682-90. PubMed ID: 27196769 [TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of salivary gland tumors. Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885 [TBL] [Abstract][Full Text] [Related]
6. State-of-the-Art Strategies for Targeting Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997 [TBL] [Abstract][Full Text] [Related]
7. RET fusion as a novel driver of medullary thyroid carcinoma. Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157 [TBL] [Abstract][Full Text] [Related]
8. Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Unger K; Malisch E; Thomas G; Braselmann H; Walch A; Jackl G; Lewis P; Lengfelder E; Bogdanova T; Wienberg J; Zitzelsberger H Oncogene; 2008 Jul; 27(33):4592-602. PubMed ID: 18408749 [TBL] [Abstract][Full Text] [Related]
9. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059 [TBL] [Abstract][Full Text] [Related]
10. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493 [TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of RET fusions in advanced colorectal cancer. Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337 [TBL] [Abstract][Full Text] [Related]
12. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779 [TBL] [Abstract][Full Text] [Related]
13. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases. Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606 [TBL] [Abstract][Full Text] [Related]
15. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574 [TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing of extraskeletal myxoid chondrosarcoma. Davis EJ; Wu YM; Robinson D; Schuetze SM; Baker LH; Athanikar J; Cao X; Kunju LP; Chinnaiyan AM; Chugh R Oncotarget; 2017 Mar; 8(13):21770-21777. PubMed ID: 28423517 [TBL] [Abstract][Full Text] [Related]
17. Decade in review: a new era for RET-rearranged lung cancers. Choudhury NJ; Drilon A Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819 [TBL] [Abstract][Full Text] [Related]
18. RET signaling pathway and RET inhibitors in human cancer. Regua AT; Najjar M; Lo HW Front Oncol; 2022; 12():932353. PubMed ID: 35957881 [TBL] [Abstract][Full Text] [Related]
19. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403 [TBL] [Abstract][Full Text] [Related]
20. RET kinase inhibitors: a review of recent patents (2012-2015). Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]